Last reviewed · How we verify
Moderate to severe rheumatoid arthritis
Approved treatments
- TNF Inhibitor · Pfizer
- Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- Chronic- PF-06480605 150 mg SC Q4W · Pfizer
- Chronic- PF-06480605 150 mg SC Q4W · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe rheumatoid arthritis patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe rheumatoid arthritis treatment landscape brief
- Moderate to severe rheumatoid arthritis treatment updates RSS
Frequently asked questions about Moderate to severe rheumatoid arthritis
What drugs treat Moderate to severe rheumatoid arthritis?
Tracked treatments include TNF Inhibitor, Chronic- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W.
What is the treatment for Moderate to severe rheumatoid arthritis?
Standard treatment for Moderate to severe rheumatoid arthritis includes TNF Inhibitor, Chronic- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe rheumatoid arthritis patent cliff · Moderate to severe rheumatoid arthritis CI report
- Treatment: TNF Inhibitor · Pfizer
- Treatment: Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- Treatment: Chronic- PF-06480605 150 mg SC Q4W · Pfizer
- Treatment: Chronic- PF-06480605 150 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing